Navigation Links
Orapred ODT Tastes Good

Survey Shows 89% of Patients Prefer Orapred ODT Over Liquid

ALPHARETTA, Ga., March 29, 2007 /PRNewswire/ -- Alliant Pharmaceuticals announced today survey results showing that children prefer Orapred ODT(TM) (Prednisolone sodium phosphate orally disintegrating tablets) over liquid steroids.(1)

The results of the patient feedback survey involving more than 900 children (n=973), showed that 89% (n=870) of the children preferred Orapred ODT over liquid versions. The results also showed that 83% (n=809) of the respondents liked the taste of Orapred ODT, and 97% (n=942) said Orapred ODT was easy to take. In addition, 96% (n=937) of the patients reported that they were able to take all of their medication as prescribed.

Orapred ODT is the first orally disintegrating tablet form of prednisolone available in the United States. Orapred ODT is prescribed primarily for acute exacerbations of asthma in children. It is also used to control severe, persistent asthma and to reduce inflammation seen in numerous medical conditions including arthritis and cancer. The indication and important safety information for Orapred ODT is listed below.

"Orapred ODT's exclusive taste-masking technology helps disguise prednisolone's typically bitter taste," said Mark Pugh, President of Alliant Pharmaceuticals. "We are pleased to see that, based on these results; patients appreciate both the taste and convenience that Orapred ODT has to offer."

Orapred ODT utilizes a proprietary orally disintegrating tablet technology to provide a taste-masked, non refrigerated and convenient formulation of prednisolone.

Alliant Pharmaceuticals sponsored the survey that was initiated in September, 2006 and ran until December 2006. Patients were included in the multi-center survey if they required steroid burst therapy for asthma exacerbation and were required to have taken a liquid steroid in the past. Physicians were instr
'"/>




Page: 1 2 3

Related medicine technology :

1. ADVENTRX Announces Positive Data From Preclinical Pharmacokinetic Testing of ANX-514 (Docetaxel Emulsion)
2. The Past, Present and Future of HLA Typing
3. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
6. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
7. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
8. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
9. ViaCell to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Accelrys to Present to Investors at C.E. Unterberg Emerging Growth Opportunities Conference
11. Metabasis to Present at C.E. Unterberg, Towbin Emerging Growth Conference and Attend Pacific Growth Equities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Orapred ODT Tastes Good
(Date:8/22/2014)... Aug. 22, 2014  Landauer, Inc. (NYSE: ... radiation measurement and monitoring, outsourced medical physics services and ... William E. Saxelby , its President and Chief Executive ... Executive Officer and as a member of the Board ... will be replaced on an interim basis by ...
(Date:8/21/2014)... AUSTIN, Texas , Aug. 21, 2014  Vermillion, ... company focused on gynecologic cancers and women,s health, has ... of Sales and Managed Markets. Ms. Bauzon ... traction and expanding payer coverage for laboratory services companies. ... most recently with PerkinElmer, Inc., where she held the ...
(Date:8/21/2014)... Aug. 21, 2014 /CNW/ - Eisai Limited is pleased to ... the first-of-its-kind comic book available in Canada ... designed specifically to educate children and their parents about epilepsy, ... affecting more than 300,000 Canadians. Eisai is guided by ... , in which the patient is central – there was ...
Breaking Medicine Technology:Landauer, Inc. Announces Executive Management Change 2Vermillion Appoints Holly B. Bauzon as VP of Sales and Managed Markets 2Eisai Pleased to Support Canadian Epilepsy Alliance Comic Book that Teaches Children About Epilepsy 2
... INDIANAPOLIS, Nov. 2, 2010 Eli Lilly and Company (NYSE: ... focused on diabetes in China, where the incidence of the disease ... in Shanghai in the second half of 2011, will focus on ... leadership in this disease area and the priority Lilly places on ...
... Back Awards is now accepting nominations to honor individuals ... The Welcome Back Awards , now in its 13th ... to recognize outstanding achievements in the fight against depression and ... Welcome Back Awards continue to motivate healthcare providers ...
Cached Medicine Technology:Eli Lilly and Company to Open a Diabetes-Focused Research Center in China 2Eli Lilly and Company to Open a Diabetes-Focused Research Center in China 3Eli Lilly and Company to Open a Diabetes-Focused Research Center in China 4The Welcome Back Awards Seeks Nominations to Honor Leaders in the Depression Community 2The Welcome Back Awards Seeks Nominations to Honor Leaders in the Depression Community 3
(Date:8/22/2014)... somatic mutation at amino acid 918 in the RET ... cell lung cancer (SCLC) tumors and enforced expression of ... signaling and cell growth. , SCLC is a highly ... lung cancers and is strongly associated with tobacco smoking. ... examined for genomic alterations and targeted therapies are approved ...
(Date:8/22/2014)... 22, 2014 Paying tuition and other ... the coming year for four nurse educators pursuing advanced ... League for Nursing Foundation for Nursing Education . This ... $28,000, $10,000 more than in 2013, thanks to these ... and Elizabeth Isaac Marcil Endowment Funds, both donated by ...
(Date:8/22/2014)... 22, 2014 Testosterone treatment lawsuits ... U.S. courts on behalf of men who allegedly ... of prescription low testosterone therapies, Bernstein Liebhard LLP ... was filed against Pfizer Inc. on July 31st ... heart issues due to his use of Depo-Testosterone. ...
(Date:8/22/2014)... CarePoint Health is proud to ... Geriatrics, Hospice and Palliative Care, Dr. Michelle Reisner, ... Their system welcomes Dr. Reisner to the community. ... CarePoint Health Medical Group, a comprehensive network of ... a wide range of specialties. This latest acquisition ...
(Date:8/22/2014)... -- Back-to-school time provides an opportunity for parents to ... schedules, an expert suggests. "Forget New Year,s resolutions; ... be the start of a new fitness and exercise ... at the University of the Sciences in Philadelphia, said ... activities likely to build up, "it,s important for mom ...
Breaking Medicine News(10 mins):Health News:Novel oncogenic RET mutation found in small cell lung cancer 2Health News:NLN Foundation for Nursing Education Announces 2014 Faculty Scholarship Awards 2Health News:NLN Foundation for Nursing Education Announces 2014 Faculty Scholarship Awards 3Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 2Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 3Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 4Health News:Dr. Reisner Joins CarePoint Health Medical Group 2Health News:With Kids in School, Parents Can Work Out 2
... Promote Patient Safety for Care Abroad, CHICAGO, ... considering traveling abroad for medical care, new guiding,principles ... American Medical,Association,s (AMA) annual policy-making meeting. The nine ... care abroad for consideration,by patients, employers, insurers and ...
... and ,lack of time, as, the top three factors that ... ... 17 Findings from a survey,released today reveal that the vast ... less than half of those who,consider making lifestyle changes (46%) are ...
... Functioning in Fibromyalgia Patients, INDIANAPOLIS, June ... (FDA) has approved Cymbalta(R) (duloxetine HCl) for ... disorder, Eli Lilly,and Company (NYSE: LLY ... serotonin-,norepinephrine reuptake inhibitor with proven efficacy for ...
... FRANCISCO, June 16 Following a study,indicating that strong ... community, Asian & Pacific Islander Wellness Center has,developed a ... of,stigma in the Chinese community., Joan Chen generously ... for the TalkAIDS campaign, where she asks "Don,t think ...
... 16 The Concerned Shareholders of Biovail,Corporation (NYSE: BVF ... of Biovail Corporation:, , June 16, 2008, William ... Mississauga Road Mississauga, Ontario l5N 8M5, Dear Mr. ... debate between the two of,us either Wednesday or Thursday of ...
... Product Line and International ... ... the leader,in legal holds and retention management solutions, announced it secured ... Lightspeed Venture Partners, Azure Capital, Granite,Ventures, and Cipio Partners, all renewed ...
Cached Medicine News:Health News:AMA Provides First Ever Guidance on Medical Tourism 2Health News:LIVESTRONG.COM Survey Reveals 86 Percent of Americans Attempt Changes to Improve Their Health but Less Than Half are Successful 2Health News:LIVESTRONG.COM Survey Reveals 86 Percent of Americans Attempt Changes to Improve Their Health but Less Than Half are Successful 3Health News:LIVESTRONG.COM Survey Reveals 86 Percent of Americans Attempt Changes to Improve Their Health but Less Than Half are Successful 4Health News:FDA Approves Cymbalta(R) for the Management of Fibromyalgia 2Health News:FDA Approves Cymbalta(R) for the Management of Fibromyalgia 3Health News:FDA Approves Cymbalta(R) for the Management of Fibromyalgia 4Health News:FDA Approves Cymbalta(R) for the Management of Fibromyalgia 5Health News:FDA Approves Cymbalta(R) for the Management of Fibromyalgia 6Health News:TalkAIDS: A&PI Wellness Center Launches a New Anti-Stigma Campaign With International Star Joan Chen 2Health News:Letter Challenges Biovail CEO to a Debate 2Health News:Letter Challenges Biovail CEO to a Debate 3Health News:PSS Systems Secures $18 Million in Financing 2Health News:PSS Systems Secures $18 Million in Financing 3Health News:PSS Systems Secures $18 Million in Financing 4
... stabilized hyaluronic acid-based dermal filler and ... the U.S. market. It is indicated ... facial wrinkles and folds (such as ... under the skins surface to replenish ...
... Response is a whole blood ... be used at the point-of-care. ... screen and data management features, ... options. QC and operator lockout ...
... clinically proven aminophylline directly to the area ... reduction with the aminophylline containing cream has ... increase in the firmness of the thighs. ... skin where it causes the body fat ...
... is a unique, non-invasive way of ... of cellulite and improving overall skin ... was used to rehabilitate scars, burns ... surprising side-affect was discovered - the ...
Medicine Products: